Stelis Biopharma’s CDMO partner receives approval for key ANDA from the USFDA
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.
Miravo to remain a Canadian controlled and operated company following closing of the transaction
Selexipag tablet is indicated in adults for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization for PAH
Pregabalin Capsules have an estimated market size of US $244 million for twelve months ending Sep 2022 according to IQVIA
The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument
Subscribe To Our Newsletter & Stay Updated